摘要
目的探讨西妥昔单抗联合奥沙利铂+卡培他滨(XELOX)方案治疗转移性结直肠癌(CRC)患者的临床疗效。方法根据治疗方法的不同将118例转移性CRC患者分为对照组(n=58)和联合组(n=60),对照组患者采用单纯XELOX方案治疗,联合组患者采用西妥昔单抗联合XELOX方案治疗。比较两组患者的近期疗效、肿瘤标志物[癌胚抗原(CEA)、糖类抗原19-9(CA19-9)、糖类抗原125(CA125)、糖类抗原50(CA50)]水平、T淋巴细胞亚群(CD3^(+)、CD4^(+)、CD8^(+))水平、不良反应发生情况及生存情况。结果联合组患者的疾病控制率为76.67%,高于对照组患者的58.62%,差异有统计学意义(P<0.05)。治疗后,两组患者的CEA、CA19-9、CA125、CA50水平均低于本组治疗前,联合组患者的CEA、CA19-9、CA125、CA50水平均低于对照组,差异均有统计学意义(P<0.05)。治疗后,联合组患者的CD3^(+)、CD4^(+)水平均高于本组治疗前及对照组,CD8^(+)水平低于本组治疗前及对照组,差异均有统计学意义(P<0.05)。两组患者腹泻、血小板减少、口腔黏膜炎、恶心呕吐、白细胞减少、脱发发生率比较,差异均无统计学意义(P>0.05)。随访18个月,联合组患者的生存率为70.00%,高于对照组患者的51.72%,差异有统计学意义(P<0.05)。结论西妥昔单抗联合XELOX方案治疗转移性CRC患者能够提高近期疗效和生存率,降低肿瘤标志物水平,改善免疫功能,且具有一定的安全性。
Objective To investigate the clinical efficacy of cetuximab combined with oxaliplatin plus capecitabine(XELOX)regimen in the treatment of patients with metastatic colorectal cancer(CRC).Method A total of 118 metastatic CRC patients were divided into control group(n=58)and combination group(n=60)according to different treatment methods.Patients in the control group were treated with the XELOX regimen alone,and patients in the combination group were treated with cetuximab combined with the XELOX regimen.The short-term curative effect,tumor markers[carcinoembryonic antigen(CEA),carbohydrate antigen 19-9(CA19-9),carbohydrate antigen 125(CA125),carbohydrate antigen 50(CA50)]levels,T lymphocyte subsets(CD3^(+),CD4^(+),CD8^(+))levels,adverse events,and survival were compared between the two groups.Result The disease control rate of the combination group was 76.67%,which was higher than 58.62%of the control group,and the difference was statistically significant(P<0.05).After treatment,the levels of CEA,CA19-9,CA125,and CA50 in the two groups were lower than those before treatment,and the levels of CEA,CA19-9,CA125,and CA50 in the combination group were lower than those in the control group,and the differences were statistically significant(P<0.05).After treatment,the levels of CD3^(+)and CD4^(+)in the combination group were higher than those before treatment and the control group,and the level of CD8^(+)was lower than that before treatment and the control group,and the differences were statistically significant(P<0.05).There were no significant differences in the incidence of diarrhea,thrombocytopenia,oral mucositis,nausea and vomiting,leukopenia,and alopecia between the two groups(P>0.05).After 18 months of follow-up,the survival rate of the combination group was 70.00%,which was higher than 51.72%of the control group,and the difference was statistically significant(P<0.05).Conclusion Cetuximab combined with the XELOX regimen in the treatment of patients with metastatic CRC could improve the short-term curative effect and survival,reduce the levels of tumor markers,improve immune function,and has certain safety.
作者
马朝峰
高丹
李茜
MAChaofeng;GAO Dan;LI Qian(Second Department of Oncology,Central Hospital of Jiaozuo Coal Industry(Group)Co.,Ltd.,Jiaozuo 454000,He’nan,China)
出处
《癌症进展》
2023年第8期887-890,899,共5页
Oncology Progress
